
The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.
Now Available On-Demand Chief Editor Tom von Gunden engages drug delivery regulatory experts Rumi Young…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create disruptions to patient care.…
Just two acquisitions in the first quarter, that of Intra-Cellular Therapies and IDRx, crossed the $1 billion mark, a notable…
Arming NK cells with enhanced antitumor activity. Source: Oberoi P, Wels WS – Oncoimmunology (2013) I attended and participated in…
Indoximod (1-methyl-D-tryptophan) In Chapter 2 of our 2017 book-length report, Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes…
Sign in to your account